Spyre Therapeutics, Inc. (SYRE) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
35.37
↑+661% vs avg
5yr avg: 4.65
30Y Low0.7·High15.8
ROE
↑
-25.2%
↓+77% vs avg
5yr avg: -111.5%
30Y Low-289%·High-25%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SYRE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Spyre Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $25.3B | $11.3B | $1.1B | $148M | $38M | $312M | $420M | $244M | $156M | $82M | $43M |
| Enterprise Value | $25.2B | $11.3B | $1.0B | $-40468161 | $8M | $302M | $335M | $230M | $133M | $69M | $-5153996 |
| P/E Ratio → | -36.92 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 167.52 | 16.28 | 16.67 | — | — | 40.11 | 15.72 | 9.20 |
| P/B Ratio | 35.37 | 15.85 | 2.11 | 0.81 | 0.75 | 3.72 | 3.00 | 4.06 | 2.31 | 1.63 | 0.68 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SYRE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | -45.68 | 3.30 | 16.13 | — | — | 34.34 | 13.26 | -1.11 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SYRE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -25.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | — | — | — | -27348.0% | -3640.2% | -350.3% | — | — | -1169.3% | -531.7% | -473.3% |
| Net Profit Margin | — | — | — | -38238.1% | -3598.8% | -351.1% | — | — | -1140.6% | -523.3% | -468.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.2% | -25.2% | -59.3% | -289.2% | -124.9% | -58.8% | -80.9% | -122.7% | -75.3% | -48.1% | -43.8% |
| ROA | -22.4% | -22.4% | -43.8% | -164.1% | -92.6% | -48.5% | -66.1% | -97.3% | -66.3% | -44.2% | -41.0% |
| ROIC | -29.7% | -29.7% | -73.9% | -2392.1% | -135.4% | -76.3% | -120.9% | -132.6% | -82.7% | -78.7% | -149.2% |
| ROCE | -32.9% | -32.9% | -48.3% | -132.3% | -115.9% | -55.9% | -77.6% | -121.4% | -77.1% | -48.7% | -44.2% |
SYRE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $86M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.09 | 0.06 | 0.04 | 0.08 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.12 | -0.17 | -1.03 | -0.60 | -0.12 | -0.61 | -0.24 | -0.33 | -0.25 | -0.76 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($86M) exceeds total debt ($0)
SYRE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Spyre Therapeutics, Inc.'s current ratio of 13.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 10.68x to 13.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.25 | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 | 9.11 | 4.06 | 7.49 | 9.77 | 16.75 |
| Quick Ratio | 13.25 | 13.25 | 11.26 | 10.68 | 4.25 | 4.91 | 9.11 | 4.06 | 7.49 | 9.77 | 16.75 |
| Cash Ratio | 12.89 | 12.89 | 11.16 | 10.61 | 3.80 | 4.62 | 8.90 | 3.92 | 7.28 | 8.94 | 16.02 |
| Asset Turnover | — | — | — | 0.00 | 0.03 | 0.17 | — | — | 0.05 | 0.09 | 0.07 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 58.77 | 15.87 | — | — | — | 215.84 | 95.82 |
SYRE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Spyre Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $346M | $47M | $7M | $3M | $3M | $2M | $1M | $832902 | $605127 | $391669 |
Peer Comparison
Compare SYRE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SYREYou | $25B | -36.9 | — | — | — | — | -25.2% | -29.7% | — |
 ARRY | $1B | -11.2 | 13.5 | 15.7 | 21.2% | 6.6% | -19.0% | 9.0% | 5.8 |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 TRMB | $15B | 35.3 | 20.1 | 110.0 | 68.3% | 16.9% | 7.3% | 6.8% | 1.8 |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 TERN | $5B | -47.3 | — | — | — | — | -29.6% | -42.2% | — |
 JANX | $878M | -7.9 | — | — | — | -1576.7% | -15.9% | -15.3% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 JNJ | $536B | 38.4 | 18.6 | 27.0 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 LLY | $921B | 42.5 | 30.6 | 102.7 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
Full SYRE Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYRE vs ARRY
Side-by-side business, growth, and profitability comparison vs Array Technologies, Inc..
Start ComparisonSYRE — Frequently Asked Questions
Quick answers to the most common questions about buying SYRE stock.
What is Spyre Therapeutics, Inc.'s P/E ratio?
Spyre Therapeutics, Inc.'s current P/E ratio is -36.9x. This places it at the 50th percentile of its historical range.
What is Spyre Therapeutics, Inc.'s ROE?
Spyre Therapeutics, Inc.'s return on equity (ROE) is -25.2%. The historical average is -89.8%.
Is SYRE stock overvalued?
Based on historical data, Spyre Therapeutics, Inc. is trading at a P/E of -36.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.